Global Anti-angiogenic Ophthalmic Agents Market: Overview
Anti-angiogenic ophthalmic agents mimic vascular endothelial growth factor (VEGF) antagonists. Due to the stimulation of vascular endothelial growth factor, new blood vessels are generated by a process known as neovascularization when the retinal pigment cells become dry, and ischemic. In the retina, leaking is caused if new blood vessels are not generated properly. This leads to the loss of vision. Anti-angiogenic ophthalmic agents are used to stop neovascularization in age-related macular degeneration. Anti-angiogenic ophthalmic agents are used for the treatment of myopic choroidal neovascularization, macular edema, macular degeneration, diabetic retinopathy, and diabetic macular edema. Diabetes patients are prone to diabetic macular edema (DME). DME is when blood vessels in the retina begin to leak into the macula, which causes swelling and thickening. The swelling does not cause blindness; however, it can lead to severe loss of central vision. Long-term diabetes leads to progressive damage to the retina, which can cause blindness. This condition is known as diabetic retinopathy. When macula, the central part of the retina is affected it causes decrease visual acuity and possible loss of central vision. This indication is known as macular degeneration.
If blood vessels in the eye start to leak fluids in the macula then this condition is characterized by macular edema. In this indication, there is swelling and thickening of macula due to accumulation of fluid in the central part of the retina, which leads to distorted and blurred vision. Visual impairment due to complications in myopia is known as myopic choroidal neovascularization. Between the sclera and the retina, there is choroid that is the vascular layer of the eye. Creation of new blood vessels in the choroid of the myopic eye is due to the elongation of antero-posterior axis that causes stress. Decrease in visual acuity is caused due to this neovascularization.
Global Anti-angiogenic Ophthalmic Agents Market: Drivers and Restraints
Increasing prevalence of diabetic macular edema, diabetic retinopathy, macular degeneration, macular edema, myopic choroidal neovascularization across the globe drives the anti-angiogenic ophthalmic agents market. The U.S. National Library of Medicine, National Institutes of Health states that approximately there are nearly 285 million diabetes mellitus patients globally, about one-third have signs of diabetic retinopathy. According to National Institutes of Health of U.S. the National Eye Institute, in the U.S., more than 1.75 million individuals are affected by macular degeneration caused due to rapid increase in the aging US population, this number is anticipated to increase to 3 million by 2020.
Global Anti-angiogenic Ophthalmic Agents Market: Key Segments
The global anti-angiogenic ophthalmic agents market can be segmented based on indication type, distribution channel, and region. In terms of indication type, the anti-angiogenic ophthalmic agents market can be categorized into myopic choroidal neovascularization, macular edema, macular degeneration, diabetic retinopathy, and diabetic macular edema. Based on distribution channel, the anti-angiogenic ophthalmic agents market can be divided into retail pharmacies, online pharmacies, and hospital pharmacies.
Geographically, the global anti-angiogenic ophthalmic agents market can be segregated into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America held the large Anti-angiogenic ophthalmic agents market share in 2016, due to increasing prevalence of DME in the region. According to the U.S. National Library of Medicine, National Institutes of Health, DME is a leading cause of blindness in young adults in developed countries. Anti-angiogenic ophthalmic agents affects 28% of type 2, and 12% of type 1 diabetic patients. Europe held the second large share of the Anti-angiogenic ophthalmic agents market in 2016, owing to increasing prevalence of myopic choroidal neovascularization were affected in 2010 in the region. The Anti-angiogenic ophthalmic agents market in Asia Pacific is anticipated to grow at a considerable pace during the forecast period. The Anti-angiogenic ophthalmic agents market in Middle East & Africa and Latin America is anticipated to grow at a considerable pace during the forecast period owing to increasing prevalence of diabetes.
Global Anti-angiogenic Ophthalmic Agents Market: Key Players
Key players of the global anti-angiogenic ophthalmic agents market include Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., and Genentech, Inc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.